Ivax Articles
LILLY TO SELL NON-CORE BUSINESSES
27 June 1994
GENERIC THREAT TO AUGMENTIN IN UK
6 June 1994
IVAX APPOINTMENT
16 May 1994
1ST QTR RESULTS MIXED FOR SMALLER US FIRMS
16 May 1994
NEW YORK STOCK COMMENT
9 May 1994
GENERIC DRUGS AND DELIVERY SYSTEMS
18 April 1994
IVAX BEGINS MARKETING OF NEW VERAPAMIL FORMULATION
11 April 1994
IVAX SUFFERS OVER GENERIC THREAT
11 April 1994
NEW YORK STOCK COMMENT
7 March 1994
SALBUTAMOL RUBRIC POSITIVE FOR MEDEVA
7 February 1994
IVAX AND KNOLL REACH AGREEMENT
10 January 1994
IVAX SEES NICHEPRODUCTS AS ITS FUTURE
20 December 1993
US 3rd QUARTER RESULTS - SOME IMPROVEMENT
6 December 1993
IVAX APPOINTMENT
23 August 1993
IVAX MAKES STRONG ADVANCES IN 2nd QTR
23 August 1993
BOOM FORECAST FOR US GENERICS HOUSES
5 July 1993
MYLAN'S TOLMETIN APPROVED IN USA
14 June 1993
US BIOTECH FIRMS POST GOOD 1st QTRs
17 May 1993
BAKER NORTON NEW LICENSE DEALS
22 March 1993
US BIOTECHNOLOGY COS REPORT 1992 RESULTS
15 March 1993
1992 SEES SMALLER COMPANY MERGERS
4 January 1993
IVAX TERMINATES AGREEMENT
21 December 1992
IVAX ALMOST "FULLY FLEDGED DRUG CO"
21 December 1992
US DRUG ANALYSTS VIEW CLINTON WIN
9 November 1992
IVAX NOTIFICATION
2 November 1992
COMPANY NEWS IN BRIEF
12 October 1992
FOCUS ON IVAX PRODUCT PIPELINE
12 October 1992
IVAX MARKETING
7 September 1992
Norton Healthcare showed an increase in total sales
22 June 1992
NORTON AND GLAXO CODEVELOP NEW MDIs
22 June 1992
Europe: Stock Commentary
8 June 1992
LATEST US QUARTERLY RESULTS: MIXED SHOWING
8 June 1992
SUCCESS IN A GLOBAL MARKETPLACE
4 May 1992
COMPANIES DO MORE LICENSING DEALS
4 May 1992
IVAX CORP ACQUIRES WAVERLEY PHARMA
27 April 1992
US PRESCRIPTION PRICES UP 8.1%IN 1991
23 March 1992
IVAX TO BUY S&N'S SOLOPAK UNIT
16 March 1992
NEW SINO-US PHARMA VENTURE IN CHINA
9 March 1992
TRIAL GO-AHEAD FOR DEPRENYL'S ALZENE
9 March 1992
ALZHEIMER'S DISEASE: US CONCERN
27 January 1992
IVAX COMPLETES GOLDLINE BUYOUT
13 January 1992
FEWER ACQUISITIONS AND MERGERS IN 1991
6 January 1992
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
